
Verastem (VSTM) Stock Forecast & Price Target
Verastem (VSTM) Analyst Ratings
Bulls say
Verastem is a financially strong company with a promising pipeline of treatments for various cancers, including NSCLC, PDAC, low-grade serous ovarian cancer, and KRAS-mutant and advanced solid tumors. The company's current drug under development for low-grade serous ovarian cancer has shown positive preliminary results and minimal side effects, while also showing potential for treating lung cancer and brain metastases. However, as a clinical-stage company, there are inherent risks involved, and investors should continue to closely monitor for any updates on the company's latest developments and trials.
Bears say
Verastem is facing mixed safety concerns from its GenFleet dataset, as its clinical trials have shown an alarming rate of grade 3/4 treatment-related adverse events (TRAEs), including gastrointestinal issues, anemia, and lowered white blood cell count. Additionally, the company's lead program, avutometinib + defactinib, may face challenges in delivering durable suppression of the RAS/RAF/MEK/ERK pathway, a known oncogenic driver in RAS-mutant solid tumors, due to the activation of focal adhesion kinase. This may limit the clinical benefits of the combination therapy and hinder the company's growth potential.
This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.
Verastem (VSTM) Analyst Forecast & Price Prediction
Start investing in Verastem (VSTM)
Order type
Buy in
Order amount
Est. shares
0 shares